CO2022016014A2 - Derivados de 4-(2,6-difluorofenoxi)-6-(trifluorometil)pirimidin-2-amina como potenciadores del receptor hmrgx1 para el tratamiento del dolor - Google Patents

Derivados de 4-(2,6-difluorofenoxi)-6-(trifluorometil)pirimidin-2-amina como potenciadores del receptor hmrgx1 para el tratamiento del dolor

Info

Publication number
CO2022016014A2
CO2022016014A2 CONC2022/0016014A CO2022016014A CO2022016014A2 CO 2022016014 A2 CO2022016014 A2 CO 2022016014A2 CO 2022016014 A CO2022016014 A CO 2022016014A CO 2022016014 A2 CO2022016014 A2 CO 2022016014A2
Authority
CO
Colombia
Prior art keywords
pain
hmrgx1
difluorophenoxy
pyrimidin
trifluoromethyl
Prior art date
Application number
CONC2022/0016014A
Other languages
English (en)
Inventor
Leonard Larry Winneroski Jr
Daryl Lynn Smith
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO2022016014A2 publication Critical patent/CO2022016014A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona un compuesto de la Fórmula I: en donde R1 es hidrógeno o metilo; y R2 es: o una sal aceptable desde el punto de vista farmacéutico de este, útil para tratar el dolor, que incluye dolor crónico, dolor lumbar crónico, dolor neuropático periférico diabético y dolor por osteoartritis.
CONC2022/0016014A 2020-05-08 2022-11-09 Derivados de 4-(2,6-difluorofenoxi)-6-(trifluorometil)pirimidin-2-amina como potenciadores del receptor hmrgx1 para el tratamiento del dolor CO2022016014A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063021806P 2020-05-08 2020-05-08
PCT/US2021/030100 WO2021225878A1 (en) 2020-05-08 2021-04-30 4-(2,6-difluorophenoxy)-6-(trifluoromethyl)pyri ml din-2 -amine derivatives as potentiators of th hmrgx1 receptor for the treatment of pain

Publications (1)

Publication Number Publication Date
CO2022016014A2 true CO2022016014A2 (es) 2022-11-29

Family

ID=76012049

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0016014A CO2022016014A2 (es) 2020-05-08 2022-11-09 Derivados de 4-(2,6-difluorofenoxi)-6-(trifluorometil)pirimidin-2-amina como potenciadores del receptor hmrgx1 para el tratamiento del dolor

Country Status (18)

Country Link
US (2) US11414389B2 (es)
EP (1) EP4146630B1 (es)
JP (1) JP7407971B2 (es)
KR (1) KR20230006563A (es)
CN (1) CN115803321A (es)
AR (1) AR122450A1 (es)
AU (1) AU2021268887B2 (es)
BR (1) BR112022022366A2 (es)
CA (1) CA3178068A1 (es)
CL (1) CL2022003097A1 (es)
CO (1) CO2022016014A2 (es)
CR (1) CR20220568A (es)
EC (1) ECSP22085947A (es)
IL (1) IL297974A (es)
MX (1) MX2022013982A (es)
PE (1) PE20231065A1 (es)
TW (1) TWI782504B (es)
WO (1) WO2021225878A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI782504B (zh) * 2020-05-08 2022-11-01 美商美國禮來大藥廠 (三氟甲基)嘧啶-2-胺化合物
KR20240072258A (ko) * 2021-11-08 2024-05-23 일라이 릴리 앤드 캄파니 hMrgX1 수용체의 강화제로서의 중수소화 (트리플루오로메틸)피리미딘-2-아민 화합물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637697A (en) * 1965-11-01 1972-01-25 Upjohn Co 6-amino-1 2-dihydro-1-hydroxy-2-iminopyrimidines
DE3842177A1 (de) 1988-12-15 1990-06-21 Basf Ag Substituierte sulfonylharnstoffe
DE19608831A1 (de) 1996-03-07 1997-09-18 Bayer Ag Substituierte Thienylsulfonyl(thio)harnstoffe
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
GB0021494D0 (en) * 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
EP1648876A1 (en) 2003-07-24 2006-04-26 Pharmagene Laboratories Ltd 5-ht sb 2b /sb receptor antagonists
US20080249081A1 (en) * 2006-10-24 2008-10-09 Roger Olsson Compounds for the treatment of pain and screening methods therefor
MX353747B (es) 2009-08-17 2018-01-26 Memorial Sloan Kettering Cancer Center Star Compuesto de union a proteina de choque termico, composiciones, y metodos para producir y usar los mismos.
US9079866B2 (en) 2013-02-04 2015-07-14 Janssen Pharmaceutica Nv Flap modulators
TWI782504B (zh) * 2020-05-08 2022-11-01 美商美國禮來大藥廠 (三氟甲基)嘧啶-2-胺化合物

Also Published As

Publication number Publication date
CA3178068A1 (en) 2021-11-11
US20220372003A1 (en) 2022-11-24
CR20220568A (es) 2022-12-07
CL2022003097A1 (es) 2023-06-16
TWI782504B (zh) 2022-11-01
JP7407971B2 (ja) 2024-01-04
AR122450A1 (es) 2022-09-14
KR20230006563A (ko) 2023-01-10
ECSP22085947A (es) 2022-12-30
US20210347738A1 (en) 2021-11-11
AU2021268887A1 (en) 2022-12-08
WO2021225878A1 (en) 2021-11-11
BR112022022366A2 (pt) 2022-12-13
EP4146630B1 (en) 2024-04-24
EP4146630A1 (en) 2023-03-15
PE20231065A1 (es) 2023-07-12
MX2022013982A (es) 2022-11-30
AU2021268887B2 (en) 2024-04-04
US11773067B2 (en) 2023-10-03
CN115803321A (zh) 2023-03-14
IL297974A (en) 2023-01-01
TW202208340A (zh) 2022-03-01
JP2023524817A (ja) 2023-06-13
US11414389B2 (en) 2022-08-16

Similar Documents

Publication Publication Date Title
CO2022016014A2 (es) Derivados de 4-(2,6-difluorofenoxi)-6-(trifluorometil)pirimidin-2-amina como potenciadores del receptor hmrgx1 para el tratamiento del dolor
UY39029A (es) Uso de compuestos de aminopropionato sustituido en el tratamiento de la infección por sars-cov-2
PE20180227A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
PE20081796A1 (es) Derivados de pirimidina
PE20160524A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
ZA202306748B (en) Glp-1r receptor agonist compound and use thereof
PE20060530A1 (es) Aril y heteroaril derivados sustituidos como moduladores del metabolismo de la glucosa
RU2014124953A (ru) Производные аминопиридина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2)
PE20140161A1 (es) Compuesto biciclico
CO6650337A2 (es) Derivados de 3- hidroxi-5 -arilisotiazol novedoso
CL2022002813A1 (es) Semaglutida para el tratamiento de esteatohepatitis no alcoholica.
EA200801001A1 (ru) Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
AR037983A1 (es) Derivados de pirido [2,1-a] isoquinolina
PE20061163A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos
PE20060240A1 (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
PE20140966A1 (es) Quinazolincarboxamida azetidinas
PE20090798A1 (es) Derivados de benzotiazol como moduladores del receptor de grelina
UY32131A (es) Compuestos de anillo fusionado y uso de los mismos
CO2022015930A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
CO2022015927A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso
PE20071024A1 (es) Derivados de tetrahidronaftalina y procedimientos para su preparacion
UY31824A (es) Nuevos compuestos
PE20091086A1 (es) Compuestos que potencian el receptor de ampa y usos de los mismos en medicina